Avience Biomedicals IPO
smelistedAbout the company
Established in 2019, Avience Biomedicals is a medical consumables and diagnostics company involved in manufacturing of in-vitro diagnostic (IVD) products, rapid test kits, reagents, analyzers, culture media and other medical devices, as well as trading and distribution of diagnostic equipment. The company has been established under the brand name, "Avienbio". It manufactures its products from an owned manufacturing facility located in Uttar Pradesh. The company also plans to expand its manufacturing and has received an allotment of 2,100 sq. mtr. commercial plot in Medical Device Park, YEIDA along with 1,000 sq. mtr. industrial plot in Yamuna expressway. The company has scaled up its product basket from primarily COVID-related diagnostics kits to include dengue, malaria, HIV, HBsAg, HCV, syphilis, typhoid and pregnancy rapid test kits, molecular diagnostics, culture media, biochemistry reagents, electrolyte analyzer, oxygen concentrator and lab consumables along with being a trader of diagnostics instruments and an authorized channel partner to some of the leading diagnostics equipment brands. The business has a diversified customer base including B2B distributors/traders, B2C hospitals and diagnostic laboratories and B2G government entities. The sales revenue comprises various sources, and B2B and B2C sales each hold over 45% of the sales revenue. The sales revenue for the period ended on January 31, 2026 is made up of 45.3% B2B sales, 45.2% B2C sales, 7.8% government sales, and 1.8% export sales. Capacity utilisation for the rapid test kits is 84.1%. The manufacturing capacity for rapid test kits has grown significantly since FY23 and the utilization of this manufacturing capacity as of January 2026 is 84.1% compared to five lakh tests utilized during FY23. Analyzer manufacturing utilization was 80.6%, while reagent and consumable manufacturing utilization was 85.2% for the period ending January 31, 2026. Majority of the sales revenue originates from North India with the two major states of Delhi and Uttar Pradesh combined contributing over 76% of total sales revenue as of January 31, 2026. The sales revenue was attributed to Delhi by 42.2% and Uttar Pradesh by 34%. The company is actively engaged in building a foothold in export markets. It has recently entered into the African market, by beginning operations in Somalia, and has received the approval for their products from the Ethiopian Food and Drug Authority (EFDA).
GMP trend (Grey Market Premium by date)
| Date | GMP (₹) | Est. Listing | Change |
|---|---|---|---|
| 22 Jun | ₹70 | ₹278 | 0 |
| 21 Jun | ₹70 | ₹278 | -15 |
| 20 Jun | ₹85 | ₹293 | 0 |
| 19 Jun | ₹85 | ₹293 | 0 |
| 18 Jun | ₹85 | ₹293 | +10 |
| 17 Jun | ₹75 | ₹283 | +12 |
| 16 Jun | ₹63 | ₹271 | -7 |
| 15 Jun | ₹70 | ₹278 | 0 |
Strengths
- Operates in the pharmaceutical and healthcare products sector with growing demand potential
- Focus on manufacturing and supplying pharmaceutical formulations and healthcare products
- Established customer relationships and distribution network
- Experienced management team with industry expertise
- Opportunity to benefit from growth in the Indian healthcare and pharmaceutical market
- Quality-focused manufacturing processes and regulatory compliance
- Scope for business expansion through increased production capacity and product portfolio diversification
- Asset creation and capacity enhancement may support future growth
Risks
- Business is subject to stringent pharmaceutical and healthcare regulations
- Dependence on approvals, licenses, and compliance requirements
- Intense competition from established pharmaceutical and healthcare companies
- Raw material price fluctuations may impact profit margins
- Customer concentration risk if revenue depends on a limited number of clients
- Product quality issues or regulatory non-compliance could adversely affect operations
- Working capital-intensive nature of the business
- Exposure to changes in healthcare policies and industry regulations
- Risks associated with scaling operations and executing expansion plans
- Financial performance may be affected by changes in market demand and competitive pressures
Financial performance (₹ Cr)
Subscription breakup (final, times)
IPO Roadmap / Timeline
IPO Opens
Completed18 Jun 2026Bidding starts for all investor categories
IPO Closes
Completed22 Jun 2026Last day to place your bid
Basis of Allotment
Completed23 Jun 2026Share allotment finalised
Refund Initiation
Completed24 Jun 2026Refunds credited for non-allottees
Credit to Demat
Completed24 Jun 2026Allotted shares credited to demat account
Listing on Exchange
Completed25 Jun 2026Shares list on NSE / BSE
Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.
Lot size & minimum investment
| Investor Type | Min Lots | Min Shares | Min Amount | Max Lots | Max Amount | Notes |
|---|---|---|---|---|---|---|
| Retail / Individual | 1 | 600 | ₹124,800 | 1 | ₹124,800 | 1 lot only |
| HNI | 2 | 1200 | ₹249,600 | 2 | ₹249,600 | Min 2 lots |
Shares reserved per category & allotment probability
| Category | Reservation | Shares Offered | Amount (₹ Cr) | Shares Bid | Subscribed | Allotment % |
|---|---|---|---|---|---|---|
| QIB | 50% | 742,575 | 15 | 0 | 0.00x | 100% |
| NII | 15% | 222,772 | 4.5 | 902,227 | 4.05x | 24.7% |
| Retail | 35% | 519,802 | 10.5 | 0 | 0.00x | 100% |
Retail is a lottery-based allotment when oversubscribed; QIB/NII get pro-rata. Probability ≈ 1 / subscription times (100% if under-subscribed).
